Saw Palmetto: Traditional Use, Constituents and Evidence

A berry with a long reputation

Somewhere along the shelf in nearly every health food shop in the country, you'll find a small bottle with the name Serenoa repens on the label. Saw palmetto. It's been there so long it starts to look like furniture , easy to walk past without asking what the plant actually is, where it comes from, or what the science behind it really says.

My nan would have called it a "men's herb" and left it at that. But the full story is more layered than that shorthand suggests, and honestly it's one I find genuinely interesting from a botanical history standpoint , not least because the traditional use predates European contact by a very long time.

Botanical background and traditional use

Serenoa repens is a low-growing fan palm native to the subtropical and coastal regions of the south-eastern United States, particularly Florida and Georgia. It produces small, dark, olive-to-black drupes , the "berries" used medicinally; and it grows densely in sandy scrublands, sometimes forming thickets stretching kilometres across.

Indigenous nations of the south-eastern US, including the Seminole people, used the fruit as food and in various traditional preparations. European settlers in the 19th century observed these uses and began incorporating the plant into botanical and eclectic medicine traditions, where it featured in formulations aimed at the male reproductive system and urinary function. By the late 1800s and early 1900s it had entered the pharmacopoeias of several countries, before largely fading from mainstream medicine mid-century as pharmaceutical drugs dominated.

It returned to widespread use from the 1970s and 1980s onward, particularly in Europe, driven partly by commercial extracts developed in France and Germany. Those European-style standardised extracts became the basis for most of the clinical research conducted over the following decades.

Key constituents

The dried ripe fruit contains a range of compounds that have attracted research attention. The lipid-soluble fraction, the part retained in most standardised liposterolic extracts, is the most studied and includes:

• Free fatty acids; predominantly oleic, lauric, and myristic acids, typically making up 60–80% of the lipid fraction.
• Phytosterols, including beta-sitosterol, campesterol, and stigmasterol.
• Fatty acid esters and monoglycerides, present in varying concentrations depending on extraction method and plant source.
• Polyprenols; long-chain isoprenoid alcohols whose biological activity is still being characterised.

The water-soluble fraction contains polysaccharides, flavonoids, and tannins, though this fraction is less represented in the liposterolic extracts that dominate the market and the literature. Understanding which fraction is responsible for which observed effects is an ongoing question in the research.

It's worth noting that "saw palmetto extract" is not a single standardised thing. The standardised extract concept covers a wide range of preparations, and saw palmetto products vary considerably in liposterolic content, extraction solvent (hexane vs CO₂ supercritical extraction producing different profiles), and declared potency. This variability is one reason the clinical literature is so difficult to interpret consistently.

For readers interested in how phytomedicine constituents interact across complex systems, our phytomedicine glossary entry covers some of the broader frameworks for thinking about plant-based preparations.

Proposed mechanisms, what the lab work shows

The most frequently cited proposed mechanism involves inhibition of 5-alpha-reductase, the enzyme that converts testosterone to dihydrotestosterone (DHT). Some in vitro work also points to anti-proliferative activity on certain cell lines and possible anti-inflammatory effects via arachidonic acid pathway modulation. These are mechanisms described in laboratory settings, they don't straightforwardly translate to confirmed clinical outcomes, and I'd push back a bit on the way some popular summaries of this plant present the lab work as settled.

There's also been some early investigation into interactions with lipid metabolism given the high fatty acid content, and at least one research group has looked at whether saw palmetto's fatty acid constituents might interact with endocannabinoid pathways; given that certain fatty acids are precursors or competitors in those pathways. If you're curious about how endogenous fatty acid-derived signalling molecules like anandamide work, or the broader architecture of the endocannabinoid system, those pages are worth a read. The possible interactions are genuinely speculative at this stage, and I don't want to overstate them, but the chemistry is there to be asked about.

The clinical research: what it says and what it doesn't

The bulk of clinical research on saw palmetto has focused on lower urinary tract symptoms in men. The two largest and most rigorously designed trials are the STEP trial (2006, NEJM) and the CAMUS trial (2011, JAMA), both funded by the US National Institutes of Health. Neither found statistically significant differences between saw palmetto extract and placebo on the primary symptom outcome measures used.

Earlier meta-analyses (particularly those from the late 1990s and early 2000s, including a widely cited Cochrane review) had suggested modest benefits. The later NIH-funded trials, using higher-quality blinding and validated outcome instruments, did not replicate those findings. A 2012 update to the Cochrane review reflected this revised picture.

It's not a clean "doesn't work" verdict either, some smaller trials using specific European liposterolic extracts with defined fatty acid profiles have reported outcomes different from the NIH trials, raising the question of whether extract quality and composition matter enormously. The honest answer is: the literature is genuinely mixed, the methodology varies, and strong conclusions in either direction aren't well-supported by the current evidence base. That caveat applies whether you're a sceptic or an enthusiast.

Understanding how bioavailability and pharmacokinetics vary between extract types also matters here; lipid-soluble fractions behave differently from aqueous preparations in terms of absorption, and that's rarely controlled for across studies.

How saw palmetto sits under Australian regulation

In Australia, saw palmetto is available as a complementary medicine and is listed on the Australian Register of Therapeutic Goods (ARTG) under the listed medicines pathway, the "AUST L" category. Listed medicines are not individually assessed for efficacy by the TGA; they're assessed for quality and safety, with the sponsor self-certifying that the product's indications fall within TGA-approved permitted indications for listed medicines.

That distinction matters. An "AUST L" number on a saw palmetto product means it has passed quality and basic safety checks, not that the TGA has evaluated and accepted any efficacy claims. Permitted indications for listed complementary medicines are conservative, sponsors cannot make claims about specific disease states without moving to a registered (AUST R) pathway, which requires clinical evidence assessment.

The Good Manufacturing Practice (GMP) requirements that apply to listed medicines in Australia do impose real quality standards on manufacturing, which is meaningful given the extract variability problem I mentioned above. But it doesn't resolve the clinical evidence questions.

Saw palmetto is not a scheduled substance under the Poisons Standard; it doesn't appear as a Schedule 4 or Schedule 8 item, and there are no import controls analogous to, say, the kava import restrictions that apply under Australian Border Force and Office of Drug Control frameworks. It is freely available over the counter.

A few things I keep coming back to

I spent an afternoon last autumn going through a copy of John King's American Dispensatory (1870 edition, a gift from a botanist friend in Stirling) and the saw palmetto entry is remarkably specific about preparation method for the time. What struck me was how much the eclectic physicians emphasised berry quality and freshness. Current research has been slow to catch up to that intuition with rigorous extraction-comparison studies, and I think that's a real gap.

My measured view: the plant has a genuinely interesting phytochemical profile and a long documented history of traditional use. The clinical evidence, read honestly, doesn't yet support confident efficacy conclusions, and the variability in extracts makes pooling studies across trials genuinely problematic. Anyone interested in it for personal use should speak with a qualified health practitioner, and check that any product they're considering carries a valid ARTG listing.

Sources

• Saw Palmetto for Benign Prostatic Hyperplasia (Cochrane Review update); NCBI / PubMed
• Bent S et al., Saw Palmetto for Benign Prostatic Hyperplasia, NEJM 2006, NCBI / PubMed
• Listed Medicines: Guidance for Industry, Therapeutic Goods Administration (TGA)
• Saw Palmetto: What the Science Says; National Centre for Complementary and Integrative Health (NCCIH), NIH

, Naomi Ellison, Botanical & phytomedicine writer